{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:14:59Z","timestamp":1777623299705,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"American Gastroenterology Association Research"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.cgh.2020.05.010","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:18:21Z","timestamp":1589152701000},"page":"1170-1179.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-2321","authenticated-orcid":false,"given":"Parambir S.","family":"Dulai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.05.010_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.gie.2015.03.1974","article-title":"Assessment of mucosal healing in inflammatory bowel disease: review","volume":"82","author":"Dulai","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2020.05.010_bib2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.05.010_bib3","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.05.010_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2019-318256","article-title":"Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial","volume":"69","author":"Panaccione","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.05.010_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/apt.15577","article-title":"Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2019.06.018","article-title":"Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases","volume":"157","author":"Dulai","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.05.010_bib7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.cgh.2019.12.020","article-title":"How do we treat inflammatory bowel diseases to aim for endoscopic remission?","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib12","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and management of loss of response to vedolizumab in inflammatory bowel disease","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.05.010_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ecco-jcc\/jjv158","article-title":"Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study","volume":"10","author":"Barreiro-de Acosta","year":"2016","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.cgh.2020.05.010_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.36469\/9791","article-title":"Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn\u2019s disease","volume":"6","author":"Perera","year":"2018","journal-title":"JHEOR"},{"key":"10.1016\/j.cgh.2020.05.010_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040622317742095","article-title":"Acute severe ulcerative colitis: latest evidence and therapeutic implications","volume":"9","author":"Dulai","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.cgh.2020.05.010_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023765","article-title":"Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial","volume":"9","author":"Thomas","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cgh.2020.05.010_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/apt.13763","article-title":"Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis","volume":"44","author":"Peyrin-Biroulet","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.gastro.2015.06.001","article-title":"Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.05.010_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.crohns.2010.12.005","article-title":"Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients","volume":"5","author":"Navaneethan","year":"2011","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.05.010_bib24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/apt.13197","article-title":"Systematic review: the financial burden of surgical complications in patients with ulcerative colitis","volume":"41","author":"Lindsay","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.010_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20390","article-title":"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model","volume":"20","author":"Archer","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cgh.2020.05.010_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40273-017-0601-6","article-title":"A\u00a0systematic review of the cost-effectiveness of biologics for ulcerative colitis","volume":"36","author":"Stawowczyk","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cgh.2020.05.010_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cgh.2013.06.028","article-title":"Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children","volume":"12","author":"Yang","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib28","article-title":"Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cgh.2020.05.010_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.giec.2010.07.008","article-title":"Cost-effectiveness of colonoscopy","volume":"20","author":"Zauber","year":"2010","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"10.1016\/j.cgh.2020.05.010_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1155\/2015\/627370","article-title":"Ulcerative colitis-associated hospitalization costs: a population-based study","volume":"29","author":"Coward","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2016-000093","article-title":"Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis","volume":"3","author":"Yokomizo","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib32","first-page":"253","article-title":"Budget impact of adding vedolizumab to a health plan formulary as another first-line biologic option for ulcerative colitis and Crohn's disease","volume":"11","author":"Wilson","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.cgh.2020.05.010_bib33","first-page":"859","article-title":"An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States","volume":"22","author":"Milev","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cgh.2020.05.010_bib34","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.cgh.2019.01.014","article-title":"Cost-effectiveness of colorectal cancer screening strategies-a systematic review","volume":"17","author":"Ran","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.crohns.2011.10.005","article-title":"Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients","volume":"6","author":"Navaneethan","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.05.010_bib36","first-page":"S-843","article-title":"Mo1801 \u2013 incorporating fecal calprotectin in clinical practice in patients with ulcerative colitis: a grade-based approach","volume":"156","author":"Dulai","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.05.010_bib37","first-page":"1472","article-title":"Safety of surveillance colonoscopy in long-standing ulcerative colitis","volume":"89","author":"Koobatian","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.MIB.0000437985.00190.aa","article-title":"Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis","volume":"20","author":"Bouguen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.05.010_bib39","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/2050640616686517","article-title":"Compliance with the faecal calprotectin test in patients with inflammatory bowel disease","volume":"5","author":"Marechal","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2020.05.010_bib40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.05.010_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(19)38495-1","article-title":"Su1858\u2013real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: results from the Evolve study","volume":"156","author":"Yarur","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.05.010_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.05.010_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.010_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00384-018-3129-0","article-title":"Timing of surgery in ulcerative colitis in the biologic therapy era-the patient's perspective","volume":"33","author":"Grone","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cgh.2020.05.010_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","article-title":"Patient preferences for surgical versus medical therapy for ulcerative colitis","volume":"20","author":"Bewtra","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.05.010_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:35:26Z","timestamp":1761543326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520306443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1542356520306443"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.05.010","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}